Equine herpesvirus 1 (EHV-1) and Equine herpesvirus 4 (EHV-4) are major viral pathogens of horses that contribute to respiratory disease, abortion, and neurological disorders, leading to economic losses in the equine industry. Accurate serological diagnosis is critical for disease surveillance and control. This study aimed to develop and validate an in-house enzyme-linked immunosorbent assay (ELISA) for detecting antibodies against EHV-1 and EHV-4 in horse sera. Serum samples previously confirmed by virus neutralization test (VNT) and a commercial ELISA were used to optimize the assay. Cut-off values were established using negative controls, and 155 serum samples were tested. The developed ELISA demonstrated 80.64% positivity for EHV-1 and 79.35% for EHV-4. When compared to VNT, the assay showed 85% specificity and 100% sensitivity. A high similarity (99%) was also observed when compared with the commercial ELISA. The overall seroprevalence was found to be 54.19% for EHV-1 and 75.48% for EHV-4, with an SN50 value of 1/10 for both. The validation results confirmed high repeatability and reliability across plates. These findings suggest that the developed in-house ELISA is a practical, cost-effective, and accurate tool for the serological monitoring of EHV-1 and EHV-4 infections in horse populations.
The envelope (env) protein of SARS-CoV-2, a pivotal component of the viral architecture, plays a multifaceted role in viral assembly, replication, pathogenesis, and ion channel activity. These features make it a significant target for understanding virus–host interactions and developing vaccines to combat COVID-19. Recent structural studies provide valuable insights into the conformational dynamics and membrane topology of the SARS-CoV-2 env protein, shedding light on its functional mechanisms. The strong homology and highly conserved structure of the SARS-CoV-2 env protein shape its immunogenicity and functional characteristics. This study examines the ability of the recombinant SARS-CoV-2 env protein to stimulate an immune response. In this study, recombinant envelope proteins were produced using the baculovirus expression system, and their potential efficacy was evaluated in both in vivo and in vitro models. Our results reveal that the env protein of SARS-CoV-2 stimulates humoral and cellular responses and highlight its potential as a promising vaccine candidate for combating the ongoing pandemic.
Equine herpesvirus type 1 (EHV-1) is a major viral pathogen of horses, causing respiratory disease, abortion, and neurological disorders, while current vaccines provide only limited protection. This study aimed to evaluate the in vitro cytoprotective potential of recombinant human interferon-gamma (rhIFN-γ) and its capacity for the reduction of cytopathic damage in equine dermal cells. The human IFN-γ gene was cloned into a bacterial expression vector, expressed in Escherichia coli, and purified using affinity chromatography. Equine dermal (ED) cells were treated with different concentrations of rhIFN-γ prior to viral challenge. Cytotoxicity was assessed using the MTT assay, and cytoprotective activity was evaluated through cytopathic effect (CPE) observations and TCID50 titration. The results demonstrated that rhIFN-γ reduced EHV-1-induced cytopathic effects in a dose-dependent manner, with the most pronounced protective activity observed at 200 and 400 ng/mL. Additionally, treated cells showed significantly higher viability compared to infected controls (p < 0.05). These findings indicate that bacterially produced rhIFN-γ exhibits both antiviral and cytoprotective effects against EHV-1 in vitro and may represent a promising candidate for the development of alternative potential antiviral strategies targeting EHV-1 infections in horses. These findings indicate that bacterially produced rhIFN-γ exhibits notable cytoprotective activity in vitro by mitigating cellular injury following EHV-1 exposure.